Crypto Surges After Trump Sways Republicans To His Stablecoin Bills
Thirteen Republicans voted against a motion to advance three pro-crypto bills, 12 of whom Trump said ... More would now vote differently. Copyright 2025 The Associated Press. All rights reserved
The price of bitcoin returned above $119,000 Wednesday morning after increasing by 1.5%, while the values of other cryptocurrencies, including Ether (5.9%), XRP (2.4%), Solana (4.8%) and Binance's BNB (1.9%) rose over the last 24 hours.
Trump, writing in a Truth Social post late Tuesday, said he had a 'short discussion' with 11 of 12 Republicans who voted Tuesday against advancing the GENIUS Act, the Digital Asset Market Clarity Act and the Anti-CBDC Surveillance State Act in the House, saying they 'agreed' to vote in favor of the bills Wednesday.
Shares of stablecoin issuer Circle rose 4% in premarket trading, returning most losses from trading on Tuesday, adding to increases for Coinbase (1.1%), BitMine (17%), SharpLink (15%) and Bit Digital (5%).
Whether the three bills advance in the House. Trump noted Speaker Mike Johnson, R-La., joined his meeting with the House Republicans and 'looks forward to taking the vote as early as possible.' Key Background
Trump has pushed the pro-crypto legislation in recent weeks, writing on Truth Social Tuesday that 'ALL REPUBLICANS' should 'VOTE YES.' House Republicans named the week of July 14 'Crypto Week' as they voted on bills they claimed would make the U.S. the 'crypto capital of the world.' The GENIUS Act would establish the first set of federal regulations for stablecoin issuers, while the Digital Asset Market Clarity Act establishes which agency regulates certain digital assets, and the Anti-CBDC Surveillance State Act prohibits the Federal Reserve from issuing a central bank digital currency.
Rep. Marjorie Taylor Greene, R-Ga., said she voted against the procedural motion Tuesday because Johnson did not allow House members to submit amendments. She argued the GENIUS Act did not include a ban on a central bank digital currency, despite the Anti-CBDC Surveillance State Act explicitly doing so. Democrats previously expressed concerns over the bills and Trump's dealings with the cryptocurrency industry, including his ties to World Liberty Financial, which issued the stablecoin USD1. Several House Democrats called for the Treasury Department to release documents related to an investigation into WLF and Trump-branded meme coins, alleging possible bribery, corruption and conflicts of interest. Sen. Elizabeth Warren, D-Mass., argued the GENIUS Act's original text would 'supercharge Donald Trump's corruption.' Further Reading Forbes Trump Says Most House GOP Holdouts Have Agreed To Back His Crypto Bills—What To Know By Sara Dorn
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Snap Stock Plunged After Earnings. Buy the Dip?
Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
